You are about to enter elocta.com.
Please select if you are a healthcare professional or a patient.
I'm a
A comparative study of PK profiles shows higher plasma levels for longer with ELOCTA vs standard half-life rFVIII*,1
FVIII; Factor VIII; IU, international units; PK, pharmacokinetics; rFVIII, recombinant Factor VIII.
*As shown in A-LONG trial, sequential PK analysis demonstrated higher factor levels for ELOCTA than standard half-life rFVIII, at any given time point at equal doses.1
†Times to 1 and 3 IU/dL above baseline (95% CI) were 4.9 (4.4-5.5) and 3.7 (3.3-4.1) days for ELOCTA vs 3.3 (3.0-3.7) and 2.5 (2.2-2.7) days for rFVIII, respectively (P<0.001).
Reference
1. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan;123(3):317–25
Most acute bleeds in A-LONG were resolved with just one injection of ELOCTA*,1
*All bleeds in all trial groups (prophylaxis/on-demand treatment).
References
1. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan;123(3):317–25.
2. ELOCTA Summary of Product Characteristics. 2019.
The most common major surgeries included: unilateral knee (n=15); elbow (n=4) and ankle (n=4) arthroplasties; arthroscopy (n=3), appendectomy (n=2); laparoscopic herniorrhaphy (n=2); thoracotomy (n=2); spinal surgery (n=2); ureteroscopy (n=2)2
*One major surgery did not have information on ELOCTA dosing on the day of surgery. One major surgery did not use ELOCTA on the day of surgery.
†Six minor surgeries did not use ELOCTA on the day of surgery.
References
1. Mahlangu JN, Ragni M, Gupta N, Rangarajana S, Klamroth R, Oldenburg J, et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost 2016;116(01):1-8.
2. Chowdary P, Ragni MV, Pabinger I, Feng J, Lethagan S, Barnowski C, Mahlangu JN. Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Efficacy for Perioperative Haemostatic Management in Severe Haemophilia A. Poster preseted at the World Federation of Hemophilia 16th International Musculoskeletal Congress, May 10–12, 2019, Madrid, Spain. P-14.
3. ELOCTA Summary of Product Characteristics. 2019.
ABR, annualised bleeding rate; rFVIII, recombinant Factor VIII.
*Data from the UK National Haemophilia Database, all UK patients switching from rFVIII to rFVIIIFc prophylaxis, 01/09/16 - 31/03/19 were identified. A within-patient comparison was conducted in patients with ≥12-months pre-switch and 6-months post-switch, compliant Haemtrack (HT) data.4
†Retrospective review of existing medical records of patients with haemophilia A who had been prescribed ELOCTA was conducted from the Children’s Hospital Los Angeles Haemostasis and Thrombosis Centre database.5
References
1. FDA. Eloctate® (rFVIIIFc) Prescribing Information. https://www.fda.gov/media/88746/download. Last accessed, May 2019.
2. ELOCTA Summary of Product Characteristics. 2020.
3. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan;123(3):317–25.
5. Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia. 2018 May; 24(3):414–19.
6. Tagliaferri A, Quintavalle G, Riccardi F, Matichecchia A, Benegiamo A, Rossi R. Benefits of switch to FVIII-FC: Experience of prophylaxis in eight patients. Abstract presented at the 9th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD); 2018 Feb 7–9; Madrid, Spain. P051.
7. Jimenez R, Nunez R, Jimenez P, Rodriguez-Martorelli FJ, Perez-Simon JA. Switch to extended half-life recombinant factor VIII FC in severe hemophilia A patients under prophylaxis. Experience in one centre. Abstract presented at the 9th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD); 2018 Feb 7–9; Madrid, Spain. P176.
8. Peyvandi F, Garagiola I, Boscarino M, Ryan A, et al. Real-life experience in switching to new extended half-life products at European haemophilia centres. Haemophilia 2019;25(6):946-952.
9. Wang M, Alvarez-Roman MT, Chowdary P, Quon DV, Schafer K. Physical activity in individuals with haemophilia and experience with recombinant factors VIII FC fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports. Blood Coagul Fibrinolysis 2016;27(27):737-744.
You are about to enter elocta.com.
Please select if you are a healthcare professional or a patient.
I'm a